Literature DB >> 16441603

Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity.

Henk Schonewille1, Leo M G van de Watering, Dominique S E Loomans, Anneke Brand.   

Abstract

BACKGROUND: Alloimmunization after exposure to red cell (RBC) alloantigens depends on genetic and acquired patient-related factors, dose and route of administration, and the immunogenicity of the antigen, but exact kinetics are still unknown. STUDY DESIGN AND METHODS: A 5-year retrospective multicenter study analyzing factors influencing the rate and specificity of RBC alloimmunization was performed, with special emphasis on the time interval between transfusion event and antibody detection. Included were clinically significant alloantibodies against the Rhesus, Kell, Duffy, Kidd, and MSs blood group systems.
RESULTS: Multivariate analysis involving 1710 immunized patients revealed that time interval between transfusion and antibody tests was strongly associated with the antibody specificity. Anti-Jk(a) and anti-Jk(b) were predominantly found in patients tested within 3 months, whereas anti-K and anti-Fy(a) were the most encountered antibodies at more than 5 years after transfusion. Of all immunized patients, new antibodies were detected within 14 days after transfusion in 299 patients (16.8%) and in 1479 patients (83.2%) after more than 14 days. Fifty percent of transfusion recipients were retested for alloimmunization because of a new transfusion indication. Eleven of 2932 patients (0.4%) retested up to 3 days after transfusion had formed new antibodies.
CONCLUSION: The time interval between transfusion and antibody test was associated with RBC antibody specificity. Because RBC antibody tests after transfusion are not routinely performed, many antibodies may (not) be detected at the time of a new transfusion event, posing the transfusion recipient at risk for transfusion delay or a (delayed) hemolytic transfusion reaction. Routine RBC antibody screening at set time intervals after transfusion would reduce these risks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16441603     DOI: 10.1111/j.1537-2995.2006.00708.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  32 in total

1.  Will Genotyping Replace Serology in Future Routine Blood Grouping? - Opinion 2.

Authors:  Hein Hustinx; Stefano Fontana; Peter Gowland; Christoph Niederhauser
Journal:  Transfus Med Hemother       Date:  2009-05-11       Impact factor: 3.747

2.  An acute haemolytic transfusion reaction due to anti-Jk.

Authors:  Maria Antonietta Villa; Marilyn Moulds; Elena Beatrice Coluccio; Mara Nicoletta Pizzi; Cinzia Paccapelo; Nicoletta Revelli; Fernanda Morelati; Francesca Truglio; Maria Cristina Manera; Alberto Tedeschi; Maurizio Marconi
Journal:  Blood Transfus       Date:  2007-04       Impact factor: 3.443

3.  Rapid clearance of transfused murine red blood cells is associated with recipient cytokine storm and enhanced alloimmunogenicity.

Authors:  Jeanne E Hendrickson; Eldad A Hod; Chantel M Cadwell; Stephanie C Eisenbarth; David A Spiegel; Christopher A Tormey; Steven L Spitalnik; James C Zimring
Journal:  Transfusion       Date:  2011-05-13       Impact factor: 3.157

4.  Incidence of Red Cell Alloantibody among the Transfusion Recipients of Universiti Kebangsaan Malaysia Medical Centre.

Authors:  Rabeya Yousuf; Suria Abdul Aziz; Nurasyikin Yusof; Chooi Fun Leong
Journal:  Indian J Hematol Blood Transfus       Date:  2012-04-25       Impact factor: 0.900

5.  Frequency of alloantibodies among chronic renal failure patients in red sea state.

Authors:  Hythum Abdullah M Babiker; Tagwa Yousif Elsayed
Journal:  Indian J Hematol Blood Transfus       Date:  2013-02-12       Impact factor: 0.900

6.  Alloimmunization is associated with older age of transfused red blood cells in sickle cell disease.

Authors:  Payal C Desai; Allison M Deal; Emily R Pfaff; Bahjat Qaqish; Leyna M Hebden; Yara A Park; Kenneth I Ataga
Journal:  Am J Hematol       Date:  2015-05-28       Impact factor: 10.047

7.  Frequency and specificity of red blood cell alloimmunization in chilean transfused patients.

Authors:  José Caamaño; Evangelina Musante; Margarita Contreras; Hernán Ulloa; Carolina Reyes; Verónica Inaipil; Nicolás Saavedra; Neftalí Guzmán
Journal:  Transfus Med Hemother       Date:  2014-12-19       Impact factor: 3.747

8.  Risk factors for red blood cell alloimmunization in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) database.

Authors:  Matthew S Karafin; Matt Westlake; Ronald G Hauser; Christopher A Tormey; Philip J Norris; Nareg H Roubinian; Yanyun Wu; Darrell J Triulzi; Steve Kleinman; Jeanne E Hendrickson
Journal:  Br J Haematol       Date:  2018-04-19       Impact factor: 6.998

9.  Genomewide association study of HLA alloimmunization in previously pregnant blood donors.

Authors:  Mark Seielstad; Grier P Page; Nathan Gaddis; Marion Lanteri; Tzong-Hae Lee; Ram Kakaiya; Lisa F Barcellos; Lindsey A Criswell; Darrell Triulzi; Philip J Norris; Michael P Busch
Journal:  Transfusion       Date:  2017-11-22       Impact factor: 3.157

10.  HLA alloimmunization is associated with RBC antibodies in multiply transfused patients with sickle cell disease.

Authors:  Marianne E McPherson; Alan R Anderson; Marta-Inés Castillejo; Christopher D Hillyer; Robert A Bray; Howard M Gebel; Cassandra D Josephson
Journal:  Pediatr Blood Cancer       Date:  2010-04       Impact factor: 3.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.